Skip to main content
TipRanks
Go Ultimate75% OFF

WDB coco Co., Ltd. (7079) AI Stock Analysis

0 Followers
JP:7079

WDB coco Co., Ltd.

(TSE/TYO:7079)

Select Model
Rating:78Outperform
Price Target:JPY 2,884.00â–²(16.06% Upside)
Action:reiterated
Date:11/18/26

Strong financial performance driven by balance sheet stability and reliable cash flows, plus highly attractive valuation from the low P/E, are the primary positives; technical weakness from moving averages and MACD provides a modest offset.

Positive Factors
Conservative Balance SheetExtremely low leverage gives WDB coco substantial financial flexibility and reduces exposure to interest costs and refinancing pressure. The conservative capital structure can support resilience through weaker operating periods while preserving capacity to invest, return capital, or pursue growth.
Negative Factors
Revenue ContractionThe FY2026 revenue decline signals a material loss of top-line momentum and creates a weaker base from which future earnings must grow. If the contraction persists, it could reduce operating leverage, limit reinvestment capacity, and make currently healthy margins harder to sustain.

WDB coco Co., Ltd. (7079) vs. iShares MSCI Japan ETF (EWJ)

0%5%10%15%20%25%30%35%JP:7079+0.27%EWJ+15.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 6.04B
Dividend Yield
3.82%
Average Volume (3M)
1,750
Price to Earnings (P/E)
0.9
Beta (1Y)
0.21
Revenue Growth
-8.78%
EPS Growth
0.01%
Country
Japan
Employees
516
Sector
Healthcare
Sector Strength
51
Industry
Specialty Business Services

WDB coco Co., Ltd. Business Overview & Revenue Model

Company Description

WDB coco Co., Ltd. offers specialized contractual services to pharmaceutical companies throughout Japan. The firm plays a crucial role in advancing pharmaceuticals and medical devices, with a particular focus on safety information management, support...

How the Company Makes Money

null

WDB coco Co., Ltd. Financial Statement Overview

Summary

Excellent balance sheet with minimal debt and strong equity growth, supported by solid cash flow generation and consistent profitability despite a recent revenue slowdown.

Income Statement

78Positive

Balance Sheet

92Very Positive

Cash Flow

85Very Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue54.01B4.82B5.33B4.60B4.07B3.62B
Gross Profit18.39B1.71B2.07B1.93B1.58B1.44B
EBITDA9.65B1.01B1.36B1.31B1.12B981.71M
Net Income6.62B679.31M912.90M857.83M743.63M647.70M
Balance Sheet
Total Assets5.93B5.70B5.60B4.67B3.67B3.14B
Cash, Cash Equivalents and Short-Term Investments4.19B3.76B3.48B2.66B2.00B1.89B
Total Debt080.41M29.81M27.12M24.32M33.52M
Total Liabilities1.05B921.26M1.30B1.10B866.02M994.57M
Stockholders Equity4.89B4.78B4.30B3.56B2.80B2.15B
Cash Flow
Free Cash Flow0521.82M1.10B753.84M469.46M719.72M
Operating Cash Flow0570.54M1.10B772.20M517.49M747.90M
Investing Cash Flow0-80.53M-88.33M-91.82M-302.97M-60.48M
Financing Cash Flow0-207.03M-195.83M-110.94M-101.21M-79.11M

WDB coco Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price2485.00

Price Trends

50DMA2564.38Negative
100DMA2573.78Negative
200DMA2589.79Negative

Market Momentum

MACD-11.45Positive
RSI44.03Neutral
STOCH51.72Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7079, the sentiment is Negative. The current price of 2485.00 is below the 20-day moving average (MA) of 2543.25, below the 50-day MA of 2564.38, and below the 200-day MA of 2589.79, indicating a bearish trend. The MACD of -11.45 indicates Positive momentum. The RSI at 44.03 is Neutral, neither overbought nor oversold. The STOCH value of 51.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7079.

WDB coco Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:7079 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:7079JP:707978OutperformJPY 5.98B0.91―3.82%-8.78%0.01%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4582JP:458248NeutralJPY 7.16B-0.82――-30.58%6.93%
JP:4539JP:453947NeutralJPY 5.57B-11.41―3.24%0.31%-194.72%
JP:4586JP:458646NeutralJPY 3.71B-3.58――-81.42%36.56%
JP:4883JP:488343NeutralJPY 3.73B-1.41―――25.34%
JP:4892JP:489242NeutralJPY 5.08B-6.53――214.65%22.18%

* Healthcare Sector Average

Performance Comparison

-50%0%50%JP:7079JP:4539JP:4582JP:4586JP:4883JP:4892Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:7079 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:7079WDB coco Co., Ltd.2485.00-3.98-0.16%
JP:4539Nippon Chemiphar Co., Ltd.1543.0068.974.68%
JP:4582Symbio Pharmaceuticals Limited71.00-33.00-31.73%
JP:4586Medrx Co., Ltd.47.00-75.00-61.48%
JP:4883Modalis Therapeutics Corporation31.00-36.00-53.73%
JP:4892Cyfuse Biomedical K.K.515.00-69.00-11.82%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026